| Curcumin Reactivates Silenced Tumor Suppressor Gene RAR? by Reducing DNA Methylation | None |
| Arsenic trioxide is a potent inhibitor of the interaction of SMRT corepressor with Its transcription factor partners, including the PML-retinoic acid receptor alpha oncoprotein found in human acute promyelocytic leukemia. | leukemia, |
| A transferable silencing domain is present in the thyroid hormone receptor, in the v-erbA oncogene product and in the retinoic acid receptor. | thyroid, |
| Altered nuclear cofactor switching in retinoic-resistant variants of the PML-RARalpha oncoprotein of acute promyelocytic leukemia. | leukemia, |
| Promyelocytic leukemia zinc finger-retinoic acid receptor alpha (PLZF-RARalpha), an oncogenic transcriptional repressor of cyclin-dependent kinase inhibitor 1A (p21WAF/CDKN1A) and tumor protein p53 (TP53) genes. | leukemia, |
| Our findings unveil a novel essential oncogenic activity of PML/RARA in Acute promyelocitic leukemia | leukemia, |
| Demonstrate that RARalpha was frequently elevated in gastric carcinoma and exerted oncogenic properties via positive feedback loop of IL-1beta/Akt/RARalpha/Akt signaling. | gastric, |
| Accelerated degradation of PML-retinoic acid receptor alpha (PML-RARA) oncoprotein by all-trans-retinoic acid in acute promyelocytic leukemia: possible role of the proteasome pathway. | leukemia, |
| Trivalent antimonials induce degradation of the PML-RAR oncoprotein and reorganization of the promyelocytic leukemia nuclear bodies in acute promyelocytic leukemia NB4 cells. | leukemia, |
| The fusion oncoprotein PML-RARalpha induces endoplasmic reticulum (ER)-associated degradation of N-CoR and ER stress. | None |
| Requirement of the coiled-coil domain of PML-RARalpha oncoprotein for localization, sumoylation, and inhibition of monocyte differentiation. | None |
| inhibition of monocyte differentiation all contribute to the oncogenic activity of PML-RARalpha | None |
| RXR is an essential component of the oncogenic PML/RARA complex in vivo. | None |
| Arsenic trioxide controls the fate of the PML-RARalpha oncoprotein by directly binding PML. | None |
| RARalpha-PLZF oncogene inhibits C/EBPalpha function in myeloid cells. | None |
| PLZF-RARalpha as an oncogenic transcriptional repressor of cyclin-dependent kinase inhibitor 1A (p21WAF/CDKN1A) and tumor protein p53 (TP53) genes | None |
| Data suggest that marginal vitamin A deficiency in pregnant rats down-regulates expression of Rara in hippocampal neurons of offspring leading to decreases in Src and Nr1 expression and causing learning and memory deficits in offspring. (Rara = retinoic acid receptor alpha; Src = proto-oncogene protein src; Nr1 = N-methyl-D-asparate receptor Nr1a) | None |
| A novel macromolecular structure is a target of the promyelocyte-retinoic acid receptor oncoprotein. | None |